2Seung KJ,Bai GH,Kim SJ,et al.The treatment of tuberculosis in south Korea.Int J Tuberc Lung Dis,2003,7:912-919.
3Center for Disease Control and Prevention.TB elimination:now is the time.2002.Available from:URL:http://www.cdcnpin.org/scripts/tb/eliminate.asp.
4Ashokraj Y,Agrawal S,Varma MV,et al.Quality control of antituberculosis fixed-dose combination formulations in the global market:an in vitro study.Int J Tuberc Lung Dis,2004,8:1081-1088.
5Sterling TR,Lehmann HP,Frieden TR.Impact of DOTS compare with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths:decision analysis.BM J,2003,326:574.
6World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva:WHO,2006.361.
4Moore M,Onorato IM,McCray E,et al.Trend in drug-resistant tuberculosis in the United States,1993-1996.JAMA,1997,1278:833-887.
5Taylor JP,Sweat DB,Suarez L.Epidemiology of drug-resistant tuberculosis in Texas.Am J Epidemiology,1999,149:359-365.
6高官聚,张广宇主编.肺结核病.第1版.长春:长春出版社,2006.6.
7世界卫生组织.WHO耐药结核病规划管理指南.2007.6.
8Guidelines for surveillance of drug resistance in tuberculosis.Geneva,World Health Organization.2003.
9Anti-tuberculosis drug resistance in the world.Third global report.The WHO/IUATLD global project on anti-tuberculosis drug esistance surveillance,1999-2002.Geneva,World Health Organization.2004.
